SEARCH

SEARCH BY CITATION

References

  • 1
    Stolk JN, Boerbooms AMT, DeAbreu RA, et al. Reduced thio-purine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:18581866.
  • 2
    Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyl-transferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716718.
  • 3
    Schwab M., Schaffeler E., Marx C., et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: Impact of thiopurine S-methyltransferase polymorphism. Phar-macogenetics 2002;12:429436.
  • 4
    Moriello KA, Bowen D., Meyer DJ. Acute pancreatitis in two dogs given azathioprine and prednisone. J Am Vet Med Assoc 1987; 191:695696.
  • 5
    Houston DM, Taylor JA. Acute pancreatitis and bone marrow suppression in a dog given azathioprine. Can Vet J 1991;32:496497.
  • 6
    Beale KM. Azathioprine for treatment of immune-mediated diseases of dogs and cats. J Am Vet Med Assoc 1988;192:13161318.
  • 7
    Beale KM, Altman D., Clemmons RR, Bolon B. Systemic toxicosis associated with azathioprine administration in domestic cats. Am J Vet Res 1992;53:12361240.
  • 8
    Rinkhardt NE, Kruth SA. Azathioprine-induced bone marrow toxicity in four dogs. Can Vet J 1996;37:612613.
  • 9
    Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329339.
  • 10
    Lewis RM. Rheumatoid arthritis. Vet Clin North Am 1994;24:697703.
  • 11
    Plumb DC. Veterinary Drug Handbook, 3rd ed. Ames , IA : Iowa State University Press; 1999.
  • 12
    Christie NT, Drake S., Meyn RE, Nelson JA. 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res 1984;44:36653671.
  • 13
    Bostrom B., Erdmann G. Cellular pharmacology of 6-mercap-tourine in acute lymphoblastic leukemia. Am J Pediatr Hematol/Oncol 1993;15:8086.
  • 14
    Coulthard SA, Rabello C., Robson J., et al. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Hematol 2000;110:599604.
  • 15
    Lennard L., Lilleyman JS. Individualizing therapy with 6-mer-captopurine and 6-thioguanine related to the thiopurine methyltrans-ferase genetic polymorphism. Ther Drug Monitoring 1996;18:328334.
  • 16
    Micheli V., Jacomelli G., Fioravanti A., et al. Thiopurine meth-yltransferase activity in the erythrocytes of adults and children: An HPLC-linked assay. Clin Chim Acta 1997;259:161168.
  • 17
    Dubinsky MC, Lamothe S., Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705713.
  • 18
    Dubinsky MC, Yang HY, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904915.
  • 19
    Lennard L., Lilleyman JS, Van Loon JA, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225229.
  • 20
    Lennard L., Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Phamacol Ther 1987;41:1825.
  • 21
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacoge-netics: Monogenic inheritance of erythrocyte thiopurine methyltrans-ferase activity. J Hum Genet 1980;32:651662.
  • 22
    Lennard L., Van Loon JA, Weinshilboum RM. Pharmacogenet-ics of acute azathioprine toxicity: Relationship to thiopurine methyl-transferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149154.
  • 23
    Evans WE, Homer M., Qin Chu Y., et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985989.
  • 24
    Evans WE, Hon YY, Bomgaars L., et al. Preponderance of thio-purine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19:22932301.
  • 25
    Sebbag L., Boucher P., Davelu P., et al. Thiopurine S-methyltrans-ferase gene polymorphism is predictive of azathioprine-induced mye-losuppression in heart transplant recipients. Transplantation 2000;69:15241527.
  • 26
    Andersen JB, Szumlanski CL, Weinshilboum RM, Schmiege-low K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/ methotrexate drug interactions in two patients with thiopurine meth-yltransferase deficiency. Acta Pediatr 1998;87:108111.
  • 27
    Dervieux T., Medard Y., Baudouin V., et al. Thiopurine methyl-transferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathio-prine. J Clin Pharmacol 1999;48:793800.
  • 28
    Jackson AP. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br J Dermatol 1997;136:132148.
  • 29
    Yates CR, Krynetski EY, Loennechen T., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608614.
  • 30
    Klemetsdal B., Tollefsen E., Loennechen T., et al. Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther 1992;51:2431.
  • 31
    McLeod HL, Pritchard SC, Githang J., et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: Evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999;9:773776.
  • 32
    Collie-Duguid ESR, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:3742.
  • 33
    Kumagai K., Hiyama K., Ishioka S., et al. Genotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Phar-macogenetics 2001;11:275278.
  • 34
    Ishioka S., Hiyama K., Sato H., et al. Thiopurine methyltransfer-ase genotype and the toxicity of azathioprine in Japanese. Intern Med 1999;38:944947.
  • 35
    Ameyaw M-M, Collie-Duguid ESR, Powrie RH, et al. Thio-purine methyltransferase alleles in British and Ghanian populations. Hum Mol Genet 1999;8:367370.
  • 36
    Lowenthal A., Meyerstein N., Ben-Zvi Z. Thiopurine methyl-transferase activity in the Jewish population of Israel. J Clin Pharmacol 2001;57:4346.
  • 37
    Dewit O., Vanheuverzwyn R., Deasager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: An in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:7985.
  • 38
    Szumlanski CL, Weinshilboum RM. Sulfasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456459.
  • 39
    Weyer N., Kroplin T., Fricke L., Iven H. Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol 2001;57:129136.
  • 40
    Lewis LD, Benin A., Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464475.
  • 41
    Bergan S., Rugstad HE, Klemetsdal B., et al. Possibilities for therapeutic drug monitoring of azathioprine: 6-Thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells. Ther Drug Monitoring 1997;19:318326.
  • 42
    White S., Rosychuk RAW, Outerbridge DA, et al. Thiopurine methyltransferase in red blood cells of dogs, cats and horses. J Vet Intern Med 2000;14:499502.
  • 43
    Foster AP, Shaw SE, Duley JA, et al. Demonstration of thio-purine methyltransferase activity in the erythrocytes of cats. J Vet Intern Med 2000;2000:552554.
  • 44
    Weinshilboum RM, Raymond FA, Pazmino PA. Human eryth-rocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323333.
  • 45
    Dawson B., Trapp R. Basic and Clinical Biostatistics, 3rd ed. Norwalk , CT : Appleton and Lange; 2000.
  • 46
    Kader HA, Wenner WJ, Telega GW, Baldassano RN. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000;30:409413.
  • 47
    Naughton MA, Battaglia E., O'Brien S., et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematous patients taking azathioprine. Rheumatology 1999;38:640644.